<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33943033</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2160-7648</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical pharmacology in drug development</Title>
          <ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.</ArticleTitle>
        <Pagination>
          <StartPage>1365</StartPage>
          <EndPage>1374</EndPage>
          <MedlinePgn>1365-1374</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.948</ELocationID>
        <Abstract>
          <AbstractText>SPN-812 (viloxazine extended-release) is a novel nonstimulant recently approved as a treatment for attention-deficit/hyperactivity disorder in children and adolescents. Given that SPN-812 is metabolized by CYP2D6 and may be coadministered with CYP2D6 inhibitors, this trial investigated the pharmacokinetics and safety of SPN-812 coadministered with the potent CYP2D6 inhibitor paroxetine. In this single-sequence, 3-treatment period study in healthy volunteers, subjects received a single oral dose of 700 mg SPN-812 alone (period 1), 20 mg daily paroxetine (10 days, period 2), followed by concurrent administration of SPN-812 and paroxetine (period 3). Blood samples were collected for 72 hours post-SPN-812 dosing and analyzed for viloxazine and its primary metabolite, 5-HVLX-gluc. Twenty-two healthy adults were enrolled; all completed the trial. The potential for drug interaction between SPN-812 and paroxetine was assessed using analysis of variance on the log-transformed pharmacokinetic parameters C<sub>max</sub> , AUC<sub>0-t</sub> , and AUC<sub>inf</sub> . The least-squares geometric mean ratios for viloxazine were (reported as the ratio of combination/SPN-812 alone) C<sub>max</sub> , 116.04%; 90%CI, 109.49%-122.99%; AUC<sub>0-t</sub> , 134.65%; 90%CI, 127.65-142.03; and AUC<sub>inf</sub> , 134.80%; 90%CI, 127.94%-142.03%. CYP2D6 inhibition resulted in a modest change (&lt;35%) on viloxazine AUCs with no change in C<sub>max</sub> . All adverse events were mild in severity.</AbstractText>
          <CopyrightInformation>© 2021 Supernus Pharmaceutics, Inc. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adeojo</LastName>
            <ForeName>Lilian W</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Odebo</LastName>
            <ForeName>Oyinkansola</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adewole</LastName>
            <ForeName>Toyin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Peibing</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maletic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, South Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Pharmacol Drug Dev</MedlineTA>
        <NlmUniqueID>101572899</NlmUniqueID>
        <ISSNLinking>2160-763X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D065690">Cytochrome P-450 CYP2D6 Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>41VRH5220H</RegistryNumber>
          <NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065690" MajorTopicYN="N">Cytochrome P-450 CYP2D6 Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CYP2D6</Keyword>
        <Keyword MajorTopicYN="Y">SPN-812</Keyword>
        <Keyword MajorTopicYN="Y">attention-deficit/hyperactivity disorder</Keyword>
        <Keyword MajorTopicYN="Y">paroxetine</Keyword>
        <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
      <CoiStatement>The protocol of the trial was designed by Supernus employees, and the study was conducted by Worldwide Clinical Trials. Z. Wang, A. Kosheleff, L. Adeojo, O. Odebo, T. Adewole, P. Qin, S. Schwabe, and A. Nasser are employees of Supernus Pharmaceuticals, Inc. V. Maletic is an employee of the University of South Carolina School of Medicine. He is a consultant for ACADIA Pharmaceuticals Inc., Alfasigma USA, Inc., Alkermes, Inc., Allergan, Eisai‐Purdue, Intra‐Cellular Therapies, Janssen, H. Lundbeck A/S, Otsuka America Pharmaceutical, Inc., Sage Pharmaceuticals, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. He serves on the speakers bureau of ACADIA Pharmaceuticals Inc., Alkermes, Inc., Allergan, Ironshore, Intra‐Cellular, Janssen, H. Lundbeck A/S, Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited, and his spouse serves on the speakers bureau of Otsuka America Pharmaceutical, Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33943033</ArticleId>
        <ArticleId IdType="pmc">PMC8597116</ArticleId>
        <ArticleId IdType="doi">10.1002/cpdd.948</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Williams D.
Antidepressants. In: Lemke TL, Williams DA, Roche VF, Zito SW, eds. Foye's Principles of Medicinal Chemistry. 7th ed.
Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>
Johnson JK, Liranso T, Saylor K, et al. A phase II double‐blind, placebo‐controlled, efficacy and safety study of SPN‐812 (extended‐release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348‐358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nasser
 A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo‐controlled trial to assess the efficacy and safety of once‐daily SPN‐812 (viloxazine extended release) in the treatment of ADHD in school‐age children. Clin Ther. 2020;42(8):1452‐1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nasser A, Liranso T, Adewole T, et al. Once‐daily SPN‐812 200 and 400 mg in the treatment of ADHD in school‐aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43:684‐700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo‐controlled trial of once‐daily viloxazine extended‐release in adolescents with attention‐deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41:370‐380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo‐controlled trial of once‐daily 400‐mg and 600‐mg SPN‐812 (viloxazine extended‐release) in adolescents with ADHD. Psychopharm Bull. 2021;51(2):43‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu C, Garcia‐Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285‐300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu C. Metabolism and in vitro drug‐drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285‐1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32394778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tulloch IF, Johnson AM. The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry. 1992;53(Feb Suppl):7‐12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1531829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34(3):262‐265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1381398</ArticleId>
            <ArticleId IdType="pubmed">1389951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol. 2002;22(2):169‐173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11910262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72(9):835‐847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9294531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219‐1227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12412820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stahl SM, Muntner N. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge, UK: Cambridge University Press; 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>
Davis BA, Nagarajan A, Forrest LR,  Singh SK. Mechanism of paroxetine (Paxil) inhibition of the serotonin transporter. Sci Rep.
2016;6:23789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4817154</ArticleId>
            <ArticleId IdType="pubmed">27032980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nevels RM, Gontkovsky ST, Williams BE. Paroxetine — the antidepressant from hell? Probably not, but caution required. Psychopharm Bull. 2016;46(1):77‐104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5044489</ArticleId>
            <ArticleId IdType="pubmed">27738376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(S350):60‐75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2530793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alfaro CL, Lam YF, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40(1):58‐66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10631623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010;70(1):78‐87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2909810</ArticleId>
            <ArticleId IdType="pubmed">20642550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism‐based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metabolism Disposition.
2003;31(3):289‐293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12584155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention‐deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7(1):27‐38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24942707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Michielsen M, Comijs HC, Semeijn EJ, Beekman AT, Deeg DJ, Kooij JS. The comorbidity of anxiety and depressive symptoms in older adults with attention‐deficit/hyperactivity disorder: a longitudinal study. J Affect Disord. 2013;148(2‐3):220‐227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23267726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen Q, Hartman CA, Haavik J, et al. Common psychiatric and metabolic comorbidity of adult attention‐deficit/hyperactivity disorder: A population‐based cross‐sectional study. PLoS One. 2018;13(9):e0204516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6157884</ArticleId>
            <ArticleId IdType="pubmed">30256837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co‐administered viloxazine extended‐release (SPN‐812) and Lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155‐162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7919699</ArticleId>
            <ArticleId IdType="pubmed">33587403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co‐administered viloxazine extended‐release (SPN‐812) and methylphenidate in healthy adults. Clin Drug Investig. 2020;41(2):149‐159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7886742</ArticleId>
            <ArticleId IdType="pubmed">33368026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mulder H, Heerdink ER, lersel EEv, Wilmink FW, Egberts AC. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross‐sectional study. Ann Pharmacother. 2007;41(3):408‐413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17341534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39‐67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22171584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wilens TE, Biederman J, Brown S, et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school‐age youths with ADHD. J Am Acad Child Adolescent Psychiatry. 2002;41(3):262‐268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11886020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kessler RC, Adler LA, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716‐723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5567978</ArticleId>
            <ArticleId IdType="pubmed">28830387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Biederman J, Newcorn JH, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148(5):564‐577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2018156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tamargo J, Le Heuzey J‐Y, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015;71(5):549‐567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4412688</ArticleId>
            <ArticleId IdType="pubmed">25870032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burns M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis. 1999;7(2):137‐143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10364779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13(6):401‐421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">324751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ban TA, McEvoy JP, Wilson WH. Viloxazine: a review of the literature. Int Pharmacopsychiatry. 1980;15(2):118‐123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7002831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kabes J, Dostal T, Nahunek K, et al. Multicentre study with viloxazine (Vivalan®) in depressed patients. Int Pharmacopsychiatry. 1980;15(4):228‐239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7021448</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
